Leukaemia is the most common cancer of childhood, accounting for a third of cases. In order to assist clinicians in its early detection, we systematically reviewed all existing data on its clinical presentation and estimated the frequency of signs and symptoms presenting at or prior to diagnosis.
Five features were present in more than 50% of children: hepatomegaly (64%), splenomegaly (61%), pallor (54%), fever (53%) and bruising (52%). An additional 8 features were present in a third to a half of children: recurrent infections (49%), fatigue (46%), limb pain (43%), hepatosplenomegaly (42%), bruising/petechiae (42%), lymphadenopathy (41%), bleeding tendency (38%) and rash (35%). 6% of children were asymptomatic on diagnosis.
Over 50% of children with leukaemia have palpable livers, palpable spleens, pallor, fever or bruising on Leukaemia is the most common cancer of childhood, with 4000 new cases annually in the United
States, and 450 in the United Kingdom.
+
Over 50% of children with leukaemia have palpable livers, palpable spleens, pallor, fever or bruising on diagnosis.
Abdominal symptoms are not typically included in national cancer guidelines for identifying children with leukaemia, yet are present in 29% (anorexia/weight loss), 12% (abdominal pain) and 11% (abdominal distension) of children respectively.
Important common musculoskeletal and bleeding manifestations are also omitted, such as mucosal bleeding (25%), joint pain (11%) and limp (15%).
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In developed countries, cancer causes more childhood deaths than any other serious illness, including meningitis. 1 Leukaemia is the most common malignancy of childhood, with an annual incidence of nearly cancer only once every 20 years. 4 The early presentation of paediatric leukaemia, with nonBspecific symptoms often mimicking the common, selfBlimiting illnesses, complicates the diagnostic challenge faced by frontBline clinicians. 5, 6 Improving the early diagnosis of cancer is a key priority for many health services. The UK's NHS Cancer
Plan, for example, stipulates that all patients with suspected cancer, including children, should be seen by a specialist within two weeks of referral. 7 Subsequent guidance from the National Institution for Health and Care Excellence (NICE) details a range of specific signs and symptoms which should alert clinicians to consider cancer in children and, in the case of leukaemia, take blood or immediately refer. 5 Despite these attempts, the vast majority of cancers in children are still not diagnosed via the two week urgent referral pathway. In one recent study, 98% of childhood cancers in the UK were identified by other routes, such as direct presentations to Emergency Departments or nonBurgent hospital referrals from primary care.
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In order to improve our understanding of the early presentation of paediatric leukaemia, we aimed to systematically identify and collate all existing data on its presenting signs and symptoms at, or before, the point of diagnosis.
We searched MEDLINE and EMBASE from inception to December 2014 using a combination of subject headings and free text incorporating the terms "leukaemia" and "diagnosis", and limited to infants, children and adolescents. Reference lists of included studies were also searched for potentially relevant studies. No language restrictions were applied. The complete search strategy is detailed online (webappendix: eSearch).
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We considered for selection all primary research studies, either retrospective or prospective, of any study design , describing the frequency of signs and symptoms at time of diagnosis for a minimum of ten children (0B18 years) with any type of leukaemia.
Studies which selected cases based on the presence of only certain clinical features of leukaemia (for example, only musculoskeletal or gastrointestinal manifestations) were excluded to avoid giving disproportionate weight to those features in the data synthesis. We also excluded studies which reported data on both adults and children, but where we were unable to extract the paediatric data.
One researcher (RC) screened titles and abstracts of all papers, excluding clearly irrelevant studies. Two researchers (RC and MT) independently reviewed the full text of remaining papers to assess eligibility.
Once we had assembled a shortBlist of studies eligible for potential inclusion using the criteria above, two reviewers (RC and MT) independently assessed the risk of bias in these studies' results, to ensure that only those studies with an acceptable risk of bias were included in this review (webappendix: eTable1). There is no single, wellBvalidated quality checklist for assessing retrospective cohort studies, and so we constructed a checklist based on relevant items from the MOOSE reporting guideline for observational studies 9 , the STROBE reporting guideline for cohort studies 10 , the NewcastleBOttowa scale for nonBrandomised studies 11 and CASP guidelines for caseBcontrol and cohort studies.
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Quality was assessed as "acceptable" or "unacceptable" in three domains: definition of leukaemia, selection of cases, and methods for extracting data on included cases. "Acceptable" for case definition required cases to be defined according to bone marrow findings. "Acceptable" for case selection required at least two of: participants' baseline characteristics clearly documented; characteristics of cases representative of children with that type of leukaemia (i.e., the age and sex distribution of cases matched the known epidemiology of paediatric leukaemias); and the sample comprising all consecutive cases over the study period or, if nonBconsecutive, reasons for omission of cases documented.
"Acceptable" for data extraction required use of a standardised data collection proforma and/or the objective measurement of signs (e.g. ultrasound confirmation of suspected organomegaly).
Disagreements between the two reviewers were discussed with a third reviewer (AVDB). Only studies considered by all reviewers to pass in two or more domains were included in this review.
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Data were extracted from included studies by one reviewer (RC) using a standardised proforma, and checked by a second reviewer (MT). We extracted study characteristics including period of study, Presenting signs and symptoms were recorded as described in each study, and numbers of children presenting with each feature noted. When a symptom or sign was not recorded in a study, no assumption was made about whether or not that feature had occurred in that population (i.e. we did not assume that absence of recording was equivalent to absence of that feature).
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We used STATA 11.1 to calculate simple proportions and standard errors of proportions for each presenting feature in each included study. Where considered clinically appropriate, features that the authors considered similar were aggregated (e.g. "petechiae", "purpura" and "petechiae/purpura" were combined into a single category, "petechiae/purpura"). Features were not aggregated when it was not clinically sensible, or when they were reported with insufficient clarity to avoid possible double counting.
We calculated pooled proportions of children presenting with each feature .
Anticipating high heterogeneity between included studies, we performed randomBeffects metaBanalysis using the DerSimonian and Laird method " # . In addition, we conducted three a priori subgroup analyses to explore reasons for heterogeneity and generate new hypotheses: (1) type of leukaemia; (2) year of publication; and (3) income status of the country in which the study was performed, as defined by Organisation for Economic Cooperation and Development (OECD) criteria at the time the study was conducted. We were conducted in 21 countries, and described presenting symptoms and signs in a total of 3,084 children (Table 1 ). All were retrospective cohorts of between 10 and 406 participants, and none compared cases with controls.
The majority of studies (n=26) identified cases from medical records alone; others also used national and regional registries of childhood leukaemias (n=4), death certificates (n=2), pathology reports (n=1), clinical trial data (n=1) and primary care records (n=1). All 33 studies extracted data from written hospital records. One study also obtained data from primary care records 42 , and another supplemented hospital records with data from a patient and/or parentBcompleted questionnaire. 123 n/a n/a n/a
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(ii) Acute promyelocytic leukemia (APML)
Chan ( All included studies defined cases using bone marrow criteria, and clearly documented participants' baseline characteristics such as age and sex, which were consistent with the known epidemiology of paediatric leukaemias (webappendix: eTable1). Only 13 studies (39%) included all consecutive cases within the study period, with a further 3 studies (9%) describing why a proportion of potentially eligible cases were excluded. In the remaining 17 studies (4%), the proportion of consecutive cases included was unclear.
One weakness of the included studies was lack of clarity about how the list of clinical features of leukaemia was generated, and at which point in the diagnostic pathway clinical features were recorded.
Fifteen studies explicitly stated that they reported signs and symptoms occurring "at diagnosis", while two studies also reported symptoms from the point of symptom onset through to diagnosis. The remaining 16 studies were unclear as to whether the symptoms reported occurred at, and/or prior to diagnosis.
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The number of different signs and symptoms reported in individual studies ranged from six to 23 (median = 11). Overall, 95 separate signs and symptoms were reported. We were able to aggregate 15 features into six overBarching categories. These were: petechiae/purpura (category derived from "petechiae", "purpura" and "petechiae/purpura"), mucosal bleeding (including "mucosal bleeding" and "bleeding gums"), anorexia/weight loss (including "anorexia", weight loss" and "anorexia/weight loss"), weakness/fatigue (including "weakness", "fatigue", "weakness/fatigue"), malaise/fatigue (including "malaise" and "malaise/fatigue"), and infections (including "infection" and "recurrent infections").
55 out of a possible 86 metaBanalyses were conducted. For the remaining 31 features, metaBanalysis was not required since the features were each present on only one study. The high heterogeneity (I 2 ) statistics in the metaBanalyses, (usually >90%), indicated that the degree of heterogeneity between studies was greater than expected by chance alone, confirmed the appropriateness of random effects metaBanalysis to generate pooled proportions ( Figure 2 ).
The 36 features which were present in ≥10% of children are shown in Figure 2 . We grouped these features into seven distinct clinical categories according to main underlying pathological process or body system affected: infiltrative, haemorrhagic, infective, systemic, musculoskeletal, gastroBintestinal and cutaneous. The most common infiltrative symptoms were hepatomegaly (64%) and splenomegaly (61%). Bruising, the most common haemorrhagic symptom, occurred in 52% of children. Fever (53%) was the most common infective symptom, and the most promiment musculoskeletal features were limb pain (43%) and bone pain (26%). Systemic features such as pallor (54%), and fatigue (46%) were also common. Finally, the most common gastrointestinal feature, anorexia/weight loss (29%) was present in almost a third of children. Those features reported in a third or more of children are in Table 2 , while those reported in < 10% of children are included in webappendix: eTable2.
There were no data on the frequencies of combinations of symptoms, nor any data from control children.
Nor was it possible to extract data on the timing of specific features, such as which presented first and last. 
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There were 14 specific features for which is was possible to calculate presenting frequencies across the subgroups 'acute' and 'chronic' leukaemia. (Figure 3 ). Certain features of acute illness, such as fever, were more common in acute leukaemia (62%, CI 51B73) than chronic leukaemia (31%, CI 13B49), whereas certain more progressive, infiltrative features, such as splenomegaly, were more prominent in chronic leukaemia (77%, CI 62B92) than acute (56%, CI 40B73)). Studies from high income settings also showed a greater prevalence of splenomegaly (76%, CI 67B85) compared with that in moderate/low 
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This is the first systematic review to describe how leukaemia presents in childhood. It collates data from over 3,000 children in 33 studies from 21 different countries. Our review adhered to rigorous methods, including a systematic search strategy, unrestricted by date or language, and explicit inclusion criteria.
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The findings therefore present the most comprehensive and internationally relevant data on presenting features available for clinicians worldwide. The main limitations of the study reflect deficits in the design and reporting of the included studies.
Although studies primarily collected contemporaneous data from medical case notes, all were conducted retrospectively. Given that included studies provided data on cases only, and not on controls, we were unable to determine diagnostic accuracy of clinical features.. The high heterogeneity between included studies, which was not accounted for by our a priori subBgroup analyses, is unsurprising, given the lack of detail in most studies about how the list of presenting features was derived. Without this, it is difficult to account for variations between studies in either the number of included features reported (which ranged from six to 23), or their frequencies. Additionally, the metaBanalysis is complicated by inconsistent, vague or ambiguous language used in individual studies to describe signs and symptoms (such as 'bleeding tendency'). Conversely, some of the terms used clearly overlap to some degree (such as "bruising", "bruising/petechiae", "cutaneous bleeding", "cutaneous/mucosal bleeding", "petechiae/purpura", all of which may or may not be identical to "bleeding tendency" in leukaemia), , which contributed to the analyses of an unwieldy 97 different presenting features.
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Systematic reviews of the presentation of other main childhood cancers (such as central nervous system tumours) have also highlighted gaps in current protocols and guidelines which need to be addressed in updated guidelines. 47 Qualitative studies indicate that even those symptom lists identified from systematic reviews may be incomplete, since they may fail to capture the full range of parentBreported symptoms, in which behavioural and affective changes in children feature prominently. Some of the most commonly presenting features we identified, such as fever, pallor and fatigue, also feature prominently in the presentation of many common, selfBlimiting diseases of childhood, and are therefore unlikely to assist frontline clinicians in discriminating between those children who do or do not have leukaemia. Others -hepatomegaly, splenomegaly, lymphadenopathy and petechiae, for exampleare more specific for leukaemia, and hence of greater value as potential red flags. Our findings emphasise the importance, in any child with unexplained illness, of a focused clinical examination which should include abdominal palpation, examining for lymphadenopathy, and careful scrutiny of the skin.
Abdominal palpation can be particularly challenging in children under five years, the peak presenting age group for paediatric leukaemia, but a palpable liver or spleen is an important red flag which should prompt urgent referral for further investigation.
The lack of evidence on combinations of clinical signs and symptoms is disappointing, as research in other domains, such as serious infections in children, has shown that combining relatively nonBspecific features may result in useful prediction rules. 49 We suggest that any child presenting with unusual symptom clusters, for example, bruising and fever or limb pain and pallor, should warrant an active search for other corroborative clinical features and consideration of a full blood count and blood film.
Our study highlights three key limitations in the current evidence base for how paediatric leukaemia presents, which are priorities for future research in this area. First, we have no data on the frequency and time of onset of symptoms from the point of onset of the first symptoms at home, through to final diagnosis. Second, we do not know how frequently different symptom clusters occur, and whether different clusters occur at different time points in the illness trajectory prior to diagnosis. Third, we cannot accounts of the diagnostic process, generating a richer understanding of the potential determinants of delay.
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